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Abstract The effects of romiplostim on bone marrow mor-
phology were evaluated in adults with immune thrombocyto-
penia (ITP). Patients with platelet counts <50×109/L, ≥1 prior
ITP therapies, and no collagen at baseline received weekly
subcutaneous romiplostim starting at 1 μg/kg, adjusted to
maintain platelet counts between 50 and 200 × 109/L.
Biopsies were scheduled after 1, 2, or 3 years of romiplostim
(cohorts 1, 2, and 3, respectively). Irrespective of scheduled
time, biopsies were performed earlier if patients discontinued
or failed to achieve/maintain a response to romiplostim.
Reticulin (silver stain) and collagen (trichrome stain) were
graded by two hematopathologists using the modified
Bauermeister scale (0–4). Of 169 patients, 131 had evaluable
biopsies; 9/131 (6.9 %) had increases of ≥2 grades on the
modified Bauermeister scale (cohort 1: 0/34; cohort 2: 2/39;
cohort 3: 7/58), including two with collagen. Three of the nine
patients had follow-up biopsies, including one patient with
collagen; changes were reversible after romiplostim discontin-
uation. Of the nine patients, one had neutropenia detected by
laboratory test and two had adverse events of anemia, both
non-serious and not treatment-related. By actual exposure (as
some biopsies did not occur as scheduled), the number of
patients with grade increases ≥2 were year 1: 3/41, year 2:
1/38, year 3: 5/52. Twenty-four patients sustained platelet
counts ≥50×109/L for ≥6 months with no ITP medications
after discontinuing romiplostim, i.e., they entered clinical
These results have been previously presented in part at the following
congress: Final results from a phase 4 open-label 3-year study evaluating
changes in bone marrow morphology in adult immune thrombocytopenia
(ITP) patients receiving the thrombopoietin mimetic romiplostim.
American Society of HematologyAnnualMeeting; December 6–9, 2014;
San Francisco, CA, USA.
Electronic supplementary material The online version of this article
(doi:10.1007/s00277-016-2682-2) contains supplementary material,
which is available to authorized users.
5 Clinical Center Department of Medicine, Thrombosis Haemostasis
Center, University of Debrecen, H-4012 Debrecen, Nagyerdei krt.
98. POB.: 20, Debrecen, Hungary
6 Medizinische Universitaet Wien, Universitaetsklinik fuer Innere
Medizin I Waehringer Guertel 18-20, A-1090 Vienna, Austria
7 University Hospital Masaryk University, Jihlavská 340/20, 625
00 Brno, Czech Republic
8 Biostatistics and Epidemiology, University of Oklahoma Health
Sciences Center, 801 NE 13th, CHB 333, Oklahoma
City, OK 73104, USA
9 Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320,
USA




1 Department of Hematology, University Hospitals Leuven, Campus
Gasthuisberg, Leuven, Belgium
2 Department of Cell Therapy and Hematology, San Bortolo Hospital,
Viale Rodolfi, 37, 36100 Vicenza, Italy
3 Dalhousie University, QEII—Bethune Building, Suite 442 Bethune
Building, 1276 South Park Street, Halifax, NS B3H 2Y9, Canada
4 St. George Hospital, UNSWMedicine, UNSW, Sydney 2052,
Australia
remission of their ITP. In conclusion, in patients with ITP
receiving romiplostim, bone marrow changes were observed
in a small proportion of patients.
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Introduction
Primary immune thrombocytopenia (ITP) is an autoimmune
disorder characterized by low platelet counts caused by both
increased platelet destruction and insufficient platelet produc-
tion [1]. Chronic ITP typically lasts longer than 12months and
rarely remits spontaneously [1]. The disorder commonly man-
ifests in the form of epistaxis, gingival bleeding, petechiae,
and bruising. Less commonly, more severe events such as
gastrointestinal bleeding and, in rare cases, intracranial bleed-
ing can occur [2].
First-line therapy for ITP includes corticosteroids, intrave-
nous immunoglobulin (IVIg), and anti-D immunoglobulin
[3–5]; however, the efficacy and durability of response for
these and subsequent treatments, such as splenectomy, azathi-
oprine, vincristine, and rituximab, vary greatly and can be
associated with toxicities that limit their extended use [2,
4–6]. Romiplostim, a thrombopoietin (TPO) receptor agonist
that activates intracellular transcriptional pathways to stimu-
late megakaryopoiesis and increase platelet production [7],
can increase platelet counts and reduce bleeding and the use
of concomitant ITP medications in patients with newly diag-
nosed, persistent, and chronic ITP [8–11].
Reticulin is a normal component of the bone marrow stro-
ma; increased reticulin is associated with various benign con-
ditions (e.g., treatment with hematopoietic growth factors),
whereas collagen fibrosis is a characteristic of myeloprolifer-
ative disease [3]. Several different grading methods can be
used to quantify reticulin [12]. In bone marrow biopsies ana-
lyzed using the modified Bauermeister scale, 95 % of healthy
individuals had grade 0–1 bone marrow reticulin and 5 % had
grade ≥2 bone marrow reticulin [12]. A retrospective analysis
of bone marrow biopsies from 40 patients with ITP reported
that reticulin was present in approximately two thirds of pa-
tients, with 50 % having grade 1, 2 % grade 0–1, 13 % grade
1–2, and 2 % grade 2 reticulin [13]. Another study found that
one third of patients with ITP had increased reticulin (grade 1–
2) in the bone marrow; no correlation was found between the
presence of reticulin and disease severity or other clinical
measures [14].
In thrombocytopenic patients with ITP, treatment with TPO
receptor agonists may be associated with increases in bone
marrow reticulin [8, 15–20]. The primary objective of this
study was to prospectively evaluate bone marrow biopsies
for collagen before and after treatment with romiplostim in
adult patients with ITP; secondary objectives included assess-
ment of reticulin as well as safety.
Methods
This phase 4, prospective, open-label, multicenter study eval-
uated changes in bone marrow reticulin and collagen in pa-
tients with ITP receiving romiplostim (Fig. 1). The study was
approved by the relevant institutional review boards or ethics
committees and conducted in accordance with the Helsinki
Declaration. All patients gave written informed consent.
Eligible patients were ≥18 years of age with ITP per
American Society of Hematology guidelines and had platelet
counts <50×109/L, ≥1 prior ITP therapy (e.g., corticosteroids,
IVIg, or splenectomy), and a baseline bone marrow biopsy
negative for collagen.
The primary endpoint was the incidence of collagen in
biopsies after up to 1, 2, or 3 years of romiplostim treatment
(cohorts 1, 2, and 3, respectively). Biopsies were performed
earlier if patients discontinued early or failed to achieve/
maintain a response to romiplostim (platelet counts
≤20 × 109/L for 4 consecutive weeks at the maximum
romiplostim dose). Patients from cohorts 1 and 2 could con-
tinue to receive romiplostim after biopsy for up to a total of
3 years. Reticulin and collagen were measured using the mod-
ified Bauermeister scale (Online Resource Table S1) [12].
Grades 0–3 measure changes in reticulin (silver staining),
whereas grade 4 is defined as a diffuse, often coarse reticulin
fiber network with areas of collagenization (trichrome stain-
ing) [12]. All samples were read by two hematopathologists at
a central laboratory, with grading discrepancies adjudicated by
an independent bone marrow panel. Secondary endpoints in-
cluded the incidence of bone marrow reticulin increases of ≥2
severity grades over baseline or to grade 4 (collagen).
Safety endpoints included adverse events (AEs), the inci-
dence of neutralizing antibody formation to romiplostim or
cross-reacting antibody to endogenous TPO, and the inci-
dence of Common Terminology Criteria for Adverse Events
grade ≥2 shift in white blood cell (neutropenia) or red blood
cell (anemia) AEs or laboratory values. AEs were specifically
monitored for myelofibrosis, defined as proliferation of abnor-
mal bone marrow stem cells resulting in fibrosis or the re-
placement of the marrow with collagenous connective tissue
fibers.
Patients received weekly subcutaneous romiplostim injec-
tions for up to 3 years, starting at 1 μg/kg, with weekly ad-
justment in increments of 1 μg/kg up to a maximum of 10 μg/
kg to target platelet counts between 50 and 200 × 109/L.
Patients also received any prescribed concomitant ITP medi-
cations or treatments deemed necessary to provide adequate
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supportive care (e.g., corticosteroids). Romiplostim was ini-
tially administered at clinic visits. At the investigator’s discre-
tion, patients who achieved a platelet count ≥50×109/L with-
out dose adjustments for 4 consecutive weeks were eligible to
self-administer romiplostim or have the injection administered
by a caregiver. Patients did not necessarily self-administer
romiplostim continuously. A post hoc analysis was performed
to identify patients exhibiting clinical remission, i.e., sustained
platelet counts ≥50×109/L for ≥6 months with no ITP medi-
cations after discontinuing romiplostim.
The analysis of study endpoints included all patients who
received at least one dose of romiplostim. All endpoints were
summarized descriptively; continuous endpoints were sum-
marized by mean (standard deviation), median (quartile 1
[Q1], quartile 3 [Q3]), minimum, and maximum values; cate-
gorical variables were summarized by frequency or percent-
age in each category.
Results
Enrollment, disposition, and exposure
At baseline, overall, patients (n=169) had a mean (standard
deviation) age of 50 (17) years; 68 % were women, median
baseline platelet count was 23×109/L (range, 0.5–130), and
60 (36 %) patients had a splenectomy before enrollment
(Table 1). Cohorts were sequentially enrolled—50 in cohort
1 (bone marrow biopsy planned for after 1 year of
romiplostim), 50 in cohort 2 (biopsy planned after 2 years),
and 69 in cohort 3 (biopsy planned after 3 years). Patients in
cohorts 1 and 2 had the option of continuing to receive
romiplostim past the time of biopsy to a maximum total of
3 years. A total of 103 (61 %) patients completed all 3 years
of the study (Online Resource Table S2). The median (Q1,
Q3) duration of treatment was cohort 1, 147 (17, 156)
weeks; cohort 2, 155 (66, 156) weeks; and cohort 3, 155
(66, 156) weeks.
Bone marrow and efficacy
Of the patients with evaluable biopsies, two patients in cohort 2
and five in cohort 3 had an increase in reticulin by ≥2 grades (not
including collagen) on the modified Bauermeister scale; two of
the patients in cohort 3 had collagen (top half of Table 2, patient
details in Table 3). Three of the nine patients with bone marrow
changes had follow-up biopsies after romiplostim discontinua-
tion. Of these, two patients with an on-study increase from grade
1 to grade 3 returned to grade 1 after 12 weeks (bone marrow
biopsy images from one of these patients are shown in Fig. 2a–
c). For the third patient, collagen was observed after 25 weeks of
romiplostim treatment; there was no evidence of collagen (grade
2 reticulin only) at follow-up for 10 weeks after romiplostim
discontinuation (bone marrow biopsy images are shown in
Fig. 2d–f). The bonemarrow biopsy on this patient with collagen
was performed early due to prolonged non-response at the max-
imal dose of romiplostim (10 μg/kg). This patient had ITP that
was unresponsive to treatment with multiple corticosteroids, da-
nazol, IVIg, and cyclosporine. Per patient refusal, there was no
follow-up biopsy for the other patient with collagen, which was
found at the scheduled 3-year biopsy. Three of the nine patients
with bone marrow changes discontinued treatment early: (1) one
due to requirement for alternative therapy (discontinued at week
10)—this patient later had a splenectomy; (2) the aforementioned
case with collagen discontinued after 25 weeks; and (3) one due
to work-up to rule out non-Hodgkin lymphoma (discontinued at
week 13; suspicion was due to atypical lymphocytes in the pe-
ripheral blood, and biopsy after treatment contained grade 3
reticulin)—the patient was judged as not having non-Hodgkin
lymphoma. As noted above, biopsies did not always occur as
scheduled, such as when patients discontinued early; results by
actual exposure duration at time of biopsy are in the bottom half
of Table 2. Grade changes in the modified Bauermeister grading
scale for all patients are shown in Online Resource Table S3.
Platelet count and romiplostim dose over time for all pa-
tients are shown in Fig. 3. Platelet counts of ≥50×109/L were
achieved by 25 % of patients after week 1 and by 50 % of
Fig. 1 Design of a study to
measure changes in bone marrow
morphology in patients with ITP
receiving romiplostim. BM bone
marrow, ITP immune
thrombocytopenia
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patients after week 2. The median romiplostim dose for the
overall population was relatively stable over time. During the
course of the study, 24 patients (14 %) entered clinical remis-
sion, i.e., they sustained platelet counts ≥50 × 109/L for
≥6 months with no ITP medications after discontinuing
romiplostim. None of these patients had bonemarrow changes
of increased reticulin of ≥2 grades or collagen. Of the 24
patients with remission, three were from cohort 1, seven from
cohort 2, and 14 from cohort 3. Median time of onset for
observed remission was 52 weeks (range, 6–124 weeks),
and median duration of remission observed during the study
was 88 weeks (range, 29–154 weeks); 21 of the 24 patients
Table 1 Baseline characteristics
Characteristic Cohort 1 (N= 50) Cohort 2 (N = 50) Cohort 3 (N= 69) All (N= 169)
Female, n (%) 27 (54.0) 38 (76.0) 49 (71.0) 114 (67.5)
Age, mean (SD), years 55.5 (17.1) 48.6 (16.5) 46.6 (16.3) 49.8 (16.9)
Platelet counta, median (range), ×109/L 26 (0.51–30.0) 18 (1.0–93.0) 25 (1.0–74.0) 23 (0.5–130.0)
Duration of ITP, median (range), years 7 (0–48) 5 (0–46) 2 (0–31) 4 (0–48)
Four or more prior ITP treatments, n (%) 15 (30) 10 (20) 10 (15) 35 (21)
Splenectomy prior to study, n (%) 22 (44) 15 (30) 23 (33) 60 (36)
Bone marrow reticulin and/or collagen grade per modified Bauermeister scaleb, n (%)
0 12 (24) 15 (30) 16 (23) 43 (25)
1 37 (74) 32 (64) 50 (73) 119 (71)
2 1 (2) 3 (6) 3 (4) 7 (4)
Per study design, patients were sequentially enrolled into three cohorts, with biopsies to be done at baseline and year 1 (cohort 1), year 2 (cohort 2), or
year 3 (cohort 3). Patients from cohorts 1 and 2 had the option to continue receiving romiplostim after bone marrow biopsies for a total of 3 years
ITP immune thrombocytopenia, SD standard deviation
a Defined as the last platelet count prior to the first dose of romiplostim
b There were no patients with grade 3 or grade 4 biopsies at baseline. Per protocol, the maximum allowable baseline grade was 3
Table 2 Number of patients with reticulin or collagen present in bone marrow biopsies as determined by silver or trichrome staining and the modified
Bauermeister scale
By cohort Cohort 1 (N= 50) Cohort 2 (N= 50) Cohort 3 (N= 69) Total (N= 169)
Bone marrow biopsies after receiving romiplostima 39 40 58 137
Biopsies evaluable for collagen (trichrome stain)b 35 39 58 132
Positive for collagen 0 0 2 (3.4 %)c 2 (1.5 %)c
Patients with biopsies evaluable for reticulin (silver stain)b 34 39 58 131
Increase in reticulin by at least two grades excluding collagen 0 2 (5.1 %) 5 (8.6 %)d 7 (5.3 %)
By exposure at time of biopsy 1 yeare 2 yearse 3 yearse Total
(N= 169)
Biopsies evaluable for collagen (trichrome stain)b 42 38 52 132
Positive for collagen 1 (2.4 %) 0 1 (1.9 %) 2 (1.5 %)c
Patients with biopsies evaluable for reticulin (silver stain)b 41 38 52 131
Increase in reticulin by at least two grades excluding collagen 2 (4.9 %) 1 (2.6 %) 4 (7.7 %) 7 (5.3 %)
ITP immune thrombocytopenia
a Three patients in cohort 1, three in cohort 2, and 10 in cohort 3 had biopsies at the end of treatment because of early discontinuation. Reasons included
lack of response/requirement for alternative therapy (n= 9), consent withdrawn (n = 4), suspected non-Hodgkin lymphoma (n= 1), difficulty dosing
(n = 1), and patient ineligibility (n= 1)
b Trichrome and silver staining results could not be obtained for all biopsies because of inadequate samples. Per bone marrow biopsy (smear and core)
comments, these biopsies had insufficient cellular marrow for evaluation
c One case: grade 4 after 25 weeks in a patient with ITP who did not respond to multiple courses of treatment; no evidence of collagen on follow-up
biopsy 10 weeks later. One case: grade 4 at end of treatment; patient refused follow-up biopsy
d The five patients with increases in reticulin by two or more grades (excluding those patients with collagen) included two patients who increased from
grade 0 to 2 and three patients who increased from grade 1 to 3
e Year 1 was defined as up to 1.5 years as some patients did not have their scheduled biopsy until months later; likewise for cohorts 2 and 3
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Table 3 Characteristics of patients with changes in bone marrow of two or more grades on the modified Bauermeister scale









2 49 M White N 82 3 (3, 3) 156a
48 F White Y 0 7 (4, 10) 13
3 81 M White N 0 9 (8, 9) 156 Anemia
30 M White N 0 10 (7, 10) 26 Present
32 F White N 72 10 (7, 10) 156
60 M White Y 5 10 (10, 10) 156 Present
29 F White N 72 9 (5, 10) 156 Neutropenia
47 F White Y 84 9 (9, 9) 156
53 F White N 0 5 (2, 7) 9 Anemia
Cytopenias were defined as Common Terminology Criteria for Adverse Events grade 2 or greater shift in white blood cell (neutropenia) or red blood cell
(anemia) adverse events or laboratory values
F female, M male, N no, Q1 quartile 1, Q3 quartile 3, Y yes
a As patients were allowed to remain on romiplostim for 3 years (i.e., even after biopsy for patients in cohorts 1 and 2), this patient had the option of
continuing treatment, which he did for another 52 weeks after biopsy at week 104
Fig. 2 Images from bonemarrow
biopsies of patients with ITP
treated with romiplostim. Bone
marrow images of a patient with
reversible increased reticulin
(silver stain) (a–c) and of another
patient with reversible collagen
(trichrome stain) (d–f). Images
are arranged as follows: screening
(a, d), end of treatment (b, e), and
follow-up after discontinuation (c,
f). As not all biopsies were stained
at the same time; there were slight
differences in staining intensity,
brightness, and tone between
timepoints for a single patient. To
more easily allow for comparison
of images of a single patient and
to correct for scanning defects,
brightness, contrast, and
saturation were adjusted using
PowerPoint. ITP immune
thrombocytopenia
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were still in remission at last observation. There were no no-
table differences between those who did and did not enter
remission in baseline demographics, disease characteristics,
and other measures (such as baseline platelet count, time to
first platelet response, and average weekly dose).
Adverse events
Online Resource Table S4 shows incidences of AEs for each
cohort including all time on romiplostim, i.e., including time
past biopsy for those in cohorts 1 and 2 who chose to continue
treatment. Seven deaths occurred during the study; none were
attributed to romiplostim (Online Resource Table S5).
Treatment-related serious AEs were seen in six patients: pul-
monary embolism in two patients and exostosis, pulmonary
thrombosis, lichenoid keratosis, and peripheral embolism in
one patient each (i.e., separate AEs). Twenty-one thromboem-
bolic AEs occurred in 15 (9 %) patients at a rate of 3.9 per 100
patient-years; events reported in more than one patient includ-
ed deep vein thrombosis (n=4) as well as cerebrovascular
accident, pulmonary embolism, thrombophlebitis superficial,
and thrombosis (all n=2). Twelve thromboembolic AEs oc-
curring in 11 patients were considered serious, including two
instances each of cerebrovascular accident, pulmonary
0
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Fig. 3 Platelet count and dose
over time for patients with ITP
treated with romiplostim. a
Platelet count over time. A
platelet count of ≥50× 109/L was
achieved by 25 % of patients after
1 week and by 50 % of patients
after 2 weeks. b Romiplostim
dose over time. ITP immune
thrombocytopenia, Q1 quartile 1,
Q3 quartile 3
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embolism, and deep vein thrombosis and one instance each of
portal vein thrombosis, pulmonary thrombosis, ischemic
stroke, peripheral embolism, myocardial infarction, and
thrombosis, the latter two occurring in the same patient.
Platelet counts prior to the thromboembolic AEs ranged from
15×109/L to 333×109/L, with a median of 157×109/L and
7/21 being ≥200×109/L. Of the 21 instances of thromboem-
bolic AEs, in 11 cases romiplostimwas continued as before; in
seven cases the dose was withheld or altered; and in three
cases romiplostim was discontinued. One patient in cohort 3
tested positive for neutralizing antibodies to romiplostim at
week 30 through the year 1 visit but was negative on a subse-
quent test (week 72); the last romiplostim dose was at week
36, but the patient maintained platelet response throughout.
No patient developed neutralizing antibodies to TPO.
Cytopenias occurred in three (33 %) patients with bone
marrow changes (Table 3) and in 17 (14 %) patients without
bone marrow changes (6 with anemia, 12 with neutropenia, 1
with both); of note, these cytopenias included changes in lab-
oratory values which were not necessarily of clinical signifi-
cance (i.e., no symptoms or other findings). In the three pa-
tients with bone marrow changes and cytopenias (all ≥2 grade
reticulin, none collagen), two had anemia and one had neutro-
penia; none of the nine patients with bone marrow changes
had both anemia and neutropenia. The case of grade 2 neutro-
penia was detected by a change in laboratory values only;
there was no associated AE. Both cases of anemia were re-
ported as AEs; neither was considered serious or treatment-
related by the treating physicians. One patient had intraopera-
tive bleeding during a splenectomy and the second had a his-
tory of esophageal and duodenal ulcers and current gastroin-
testinal bleeding. The small number of patients with bone
marrow changes and cytopenias precluded any statistical com-
parisons. AEs were also examined by reticulin status (Online
Resource Table S6). While the data do not support a formal
statistical comparison, the data suggest that there were no
notable differences in AEs (i.e., in proportion of AEs by grade,
leading to discontinuation, etc.) between those with and with-
out bone marrow changes.
Self-administration
Patients self-administering romiplostimwere generally similar
to those who did not self-administer romiplostim (Online
Resource Table S7); however, there could have been either
self-selection or selection by the investigators as to who self-
administered romiplostim. After initiating self-administration,
51 patients (46 %) had ≥3 dose adjustments. Platelet counts
and dose over time are shown for those who self-administered
romiplostim (n=112) and those who did not self-administer
romiplostim (n=57) (Fig. 4). Platelet response was observed
in 98% (110/112) of those self-administering romiplostim and
79 % (45/57) of those not self-administering romiplostim.
There were no new safety concerns with patients who self-
administered romiplostim.
Discussion
Increases in bone marrow reticulin and/or collagen may be asso-
ciated with benign or malignant conditions [3]. Such increases
have been observed in healthy individuals [12, 21] and in pa-
tients with ITP not being treated with TPO receptor agonists
[13]. In this study, an increase in modified Bauermeister score
of ≥2 grades and/or collagen occurred in nine of 131 patients
(6.9 %) treated with romiplostim; seven had increased reticulin
only and two also had collagen. Of these nine patients, only three
discontinued romiplostim early; the reasons were (1) non-re-
sponse, (2) non-Hodgkin lymphoma work-up, which was nega-
tive, and (3) need for alternative therapy.While five of these nine
patients had a platelet response ≤5 % of the time, two of the five
received romiplostim for all 3 years per investigator’s decision.
The low incidence of the presence of collagen and increased
reticulin is consistent with results of past romiplostim trials; how-
ever, bone marrow biopsies were not required in those trials and
were performed at the investigators’ discretion [18, 19]. This
study is unique in that it prospectively examined bone marrow
changes in patients with ITP treated with romiplostim.
These results are also consistent with previous studies ex-
amining the effects of TPO receptor agonists (primarily
romiplostim and eltrombopag) on the bonemarrow of patients
with ITP [16, 17, 22–24]. In a small study of eight patients
with ITP treated with TPO receptor agonists, increases of one
grade on the European Consensus myelofibrosis (MF) scale
were observed in four patients, with a mean duration of expo-
sure to TPO receptor agonists of 2.7 years [23]. The MF scale
has four categories (MF-0: scattered reticulin to MF-3: coarse
collagen bundles) as compared with the five grades of the
modified Bauermeister scale used in this study (0: no reticulin
to 4: coarse fibers with collagen). A recent study of 66 patients
with ITP treated with TPO receptor agonists (about half were
treated with romiplostim and half with eltrombopag; some
patients received both and/or experimental TPO receptor ag-
onists) for at least 2 years found significantly higher rates of
MF-2/3 associated with treatment, increasing from 9 % at the
beginning of treatment to 32 % at the end of treatment [22].
For eltrombopag specifically, a study of 91 patients treated
with eltrombopag found increases of one grade in 35 patients
and two to three grades in two patients at 1 year; collagen was
found in three patients [16]. Further, in an extension study, of
232 on-treatment bone marrow biopsies from 117 patients
treated with eltrombopag for up to 5.5 years, reticulin fibrosis
characterized as moderate-to-marked was found in two pa-
tients; after eltrombopag discontinuation, this fibrosis was re-
versible in one patient. Of note, none of the biopsies on
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treatment were prompted by abnormal laboratory results or
symptoms related to possible bone marrow pathology [24].
The incidence of collagen and reticulin in our study increased
from cohort 1 to cohort 2 to cohort 3. Incidences were too small
to derive statistical significance, and the study design (biopsies
on three different cohorts with the exact time of onset of bone
marrow changes unknown) precludes the assessment of whether
the risks of collagen and reticulin increased over time. In any
case, when biopsy results were assessed by exposure at time of
biopsy rather than by cohort (as bone marrow biopsies were
performed earlier than scheduled in some patients), bonemarrow
changes did not appear to increase with time. For patients who
had collagen or increases of ≥2 grades on the modified
Bauermeister scale and follow-up biopsies (three of the nine),
follow-up biopsies showed decreases to grade 1 or 2; therefore,
bone marrow changes appear to be reversible after discontinua-
tion of romiplostim, which is consistent with previous studies
[18]. Of the nine patients with bone marrow changes, six re-
ceived high doses of romiplostim (9 or 10 μg/kg); per protocol,
if a patient did not respond to treatment, then the romiplostim
dose was escalated up to a maximum of 10 μg/kg. Further, five
of the nine patients had a low (0–5 %) percentage of time with a
platelet response and three of these patients received high doses
of romiplostim. A post hoc analysis of patients from cohort 3
indicated that the likelihood of bone marrow changes was lower






























































aFig. 4 Platelet count and dose
over time for patients with ITP
treated with romiplostim by self-
administration status. a Platelet
count over time by self-
administration status. b
Romiplostim dose over time by
self-administration status. ITP
immune thrombocytopenia, Q1
quartile 1, Q3 quartile 3
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on unadjusted p value, as in Table 4). However, this finding
should be interpreted with caution, as it may be that a higher
cumulative romiplostim dose and the occurrence of bone mar-
row changes were both downstream effects of other patient char-
acteristics such as baseline bone marrow function, i.e., these
findings could be associated with each other but not causally
related. Further study would be needed to determine to what
extent and how romiplostim dose/exposure and bone marrow
findings are related. Three of the nine patients with bone marrow
changes had cytopenias: a case of neutropenia detected by labo-
ratory results and two AEs of anemia, neither of which was
considered serious or treatment-related. In one case of anemia,
the patient had intraoperative bleeding from a splenectomy, and
in the other, the patient had gastrointestinal bleeding. Regarding
thromboembolic AEs, while 21 AEs in 15 patients (or 9 %)
might seem high, it should be kept in mind that this was over
the course of 169 patients receiving romiplostim for up to 3 years.
The duration-adjusted rate of thromboembolic AEs, 3.9 per 100
patient-years, is similar to that seen in an integrated database of
romiplostim ITP studies (7.5 per 100 patient-years) [19].
Limitations of this study include the lack of within-patient
comparison over time, as each patient was to have two biopsies
only: one baseline biopsy and one after 1, 2, or 3 years of
romiplostim (as opposed to having biopsies performed at all
four timepoints). This study design was chosen to minimize
patient discontinuation due to repeated bone marrow biopsies.
This study also did not include a placebo control group, which
limits analysis of the potential effects of romiplostim on the
bone marrow as opposed to effects due to the progression of
severe ITP. Also, the cohorts were not randomized, but enrolled
sequentially, so as to ensure adequate enrollment in each of the
cohorts before starting to enroll in the next cohort. While the
patients in cohort 3 appear to be somewhat younger and with
shorter duration of ITP, these changes are not statistically dif-
ferent. It is possible that patients with earlier-stage ITP were
more willing to enroll in cohort 3, as there was the opportunity
to receive up to 3 years of romiplostim prior to follow-up bi-
opsy. Of note, in Ghanima et al. [22], a higher grade of fibrosis
was associated with older age (p=0.01), which we did not find
in this study; the association with ITP duration was not signif-
icant (p≥ 0.05 in both analyses) in either study. A further
limitation is that while all patients had bone marrow biopsies
done at baseline, some patients did not have follow-up biopsies
(32/169, or 19 %) and a few did not have evaluable biopsies.
The rate of bone marrow changes of collagen and/or ≥2 grades
on the modified Bauermeister scale was low and limited statis-
tical interpretation and comparison, particularly for any sub-
groups, and there was a relatively short duration of follow-up
in determining the clinical importance of bone marrow chang-
es. Lastly, the exact time of when bone marrow changes oc-
curred is not known; it can only be stated that it occurred prior
to the time of biopsy, which limits assessment of any relation-
ship between time of exposure and bone marrow changes.
In conclusion, our data indicate that in patients with ITP treat-
ed with romiplostim, there was a low incidence of bone marrow
changes (nine in 131 evaluable biopsies, or 6.9 %). Whether
these observations are specifically related to romiplostim expo-
sure and response, i.e., those patients responding well at lower
doses being at lower risk of developing bone marrow changes
than those requiring higher doses, requires further evaluation.
The low incidence of both collagen and increased reticulin is
consistent with previous romiplostim studies.
Given the caveats described above, although analyses of
romiplostim ITP trials of over 600 patients treated for up to
5 years have not shown a bone marrow signal [8, 19], it is
possible that longer duration of treatment and higher doses of
Table 4 Analysis of patients with and without changes in bone marrow biopsies per the modified Bauermeister scale
Cohort 3 Patients with Δ reticulin
and/or collagena (N= 7)
Patients with no Δ collagen
or reticulin (N= 51)
Age, median (Q1, Q3), years 47 (30, 60) 44 (33, 61)
ITP duration, median (Q1, Q3), years 4.1 (1.2, 9.1) 2.2 (1.2, 7.1)
Prior splenectomy rate, n (%) 2 (29) 17 (33)
Platelet responseb, median (Q1, Q3) Time to first platelet response, weeks 15 (7, 21)c 3 (2, 8)d
Weeks with platelet response, % 5 (0, 28) 38 (28, 76)
Exposuree, median (Q1, Q3) Average weekly dose, μg/kg 9 (7, 9) 2 (1, 5)
Maximum weekly dose, μg/kg 10 (9, 10) 4 (3, 10)
Cumulative dose, μg/kg 1207 (204, 1358) 345 (136, 610)
ITP immune thrombocytopenia, Q1 quartile 1, Q3 quartile 3, Δ change, i.e., increase of two or more grades
a Five had increased reticulin only and two also had collagen
b Calculated only for those patients who had a platelet response within each group of patients
cN= 4
dN= 50
e Exposure was up to time of biopsy; per protocol, maximum dose was 10 μg/kg
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TPO receptor agonists may lead to an increase in bone marrow
changes, which in turn could lead to changes in peripheral
blood counts. As physicians may be aware, as romiplostim
may increase the risk of reticulin fibers in the bone marrow,
the prescribing information recommends that detection of any
peripheral blood cell abnormalities (such as tear drop cells or
any other phenomena leading to clinical suspicion) may neces-
sitate a bone marrow biopsy [25]. If an increase in reticulin or
fibrosis is found in the bone marrow, physicians may wish to
discontinue treatment with TPO receptor agonists. With regard
to a potential increase in reticulin/collagen deposition during
treatment with TPO receptor agonists, there is not yet consen-
sus on optimal follow-up or whether and at what intervals bone
marrow biopsies should be performed in patients treated with
TPO receptor agonists. In cases of patients having cytopenias,
performing bone marrow biopsies seems advisable.
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